Edmonston vaccine strains of measles virus (MV) have significant antitumor activity in mouse xenograft models of ovarian cancer (OvCa). MV engineered to express the sodium iodide symporter gene (MV-NIS) facilitates localization of viral gene expression and offers a tool for tumor radiovirotherapy. Here we report results from a clinical evaluation of MV-NIS delivery in patients with taxol and platinum resistant OvCa. MV-NIS was given intraperitoneally every 4 wk for up to 6 cycles. Treatment was well tolerated and associated with promising median overall survival in these heavily pretreated OvCa patients: no dose limiting toxicity was observed in 16 patients treated at high dose levels (10 
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Introduction
Ovarian cancer (OvCa) is the second most common malignancy of the female genital tract in the United States, causing an estimated 14,000 deaths in 2013 (1). Despite aggressive initial therapy, including debulking surgery followed by taxane/platinum-based regimens, the majority of the patients relapse. While OvCa is often initially sensitive to platinum-based chemotherapy, patients ultimately develop resistance. For resistant disease, patients are generally treated with agents such as liposomal doxorubicin (2, 3) , topotecan (4), weekly paclitaxel (5, 6) or gemcitabine (2) . Bevacizumab has also demonstrated some activity (7, 8) , but most clinical trials in patients with platinum-resistant ovarian cancer report median overall survival times in the order of 12 months or less (2) (3) (4) (5) (6) (7) (8) . There is a pressing need for more effective treatments in order to improve the outcome of these patients.
Virotherapy is a treatment approach with mechanisms of action that are not cross resistant with chemotherapy, Moreover, virotherapy approaches with conditionally replicating viruses have the potential to overcome an important limitation of gene transfer approaches using non-replicating vectors, i.e., their limited infection/transduction efficiency (9) . Since recurrent ovarian cancer remains confined in the peritoneal cavity in more than 80% of the patients, it provides a therapeutic opportunity for locoregional administration of novel therapeutics, including virotherapy agents. Despite promising preclinical work with different virotherapy agents (10) , however, only a handful of clinical virotherapy trials have been reported. Early work with the conditionally replicating E1B attenuated adenovirus Onyx-015 in OvCa showed no evidence of antitumor efficacy (11) ; this possibly reflected low expression levels of the native adenoviral receptor CAR (coxsackie-adenovirus-receptor) in ovarian tumors (12) , a problem that a recently completed phase I trial with replicating adenovirus AD5.SSTR/TK.RGD (allowing CAR independent infection) (13, 14) attempted to overcome.
Measles virus (MV) is a negative strand enveloped RNA virus (4), with six genes encoding 8 proteins (4). The H-protein is the surface glycoprotein that mediates MV attachment to its three known receptors, the CD46 molecule (15) the signaling lymphocyte activating molecule (SLAM) receptor (predominantly present on activated B, T cells and monocytes) (16) and the recently identified epithelial receptor nectin-4 (17) . The F-protein is responsible for cell fusion following viral attachment. Cells infected by MV express F and H proteins on their membranes and, therefore, become highly fusogenic, causing fusion with uninfected neighboring cells, with the characteristic cytopathic effect of syncytia formation. Of note, natural infection with MV has been associated with spontaneous tumor regression in patients with Hodgkin's disease and nonHodgkin's lymphoma (18, 19) . Although the wild type MV can lead to a potentially serious infectious disease, attenuated strains (vaccine strains) of MV have an outstanding safety record (20) .
Of importance and in contrast to variable expression of receptors for other viral vectors, two of the three receptors for the measles virus are consistently expressed at high levels on ovarian tumors. This includes the CD46 receptor or complement cofactor protein (21) , the expression of which allows tumor cells to evade complement-mediated lysis (22) and nectin-4 (23).
5
The sodium iodide symporter (NIS) is a membrane ion channel expressed on thyroid follicular cells that allows iodide trapping. NIS expression in thyroid tissue has been exploited for more 
Materials and Methods

Patient Selection
Eligible patients had persistent, recurrent or progressive epithelial ovarian cancer or primary peritoneal cancer after prior treatment with platinum compounds and taxanes. Histologic confirmation of the original or recurrent tumor was required. Patients had to be ≥ 18 yo with adequate hematologic, liver and kidney function, as defined by absolute neutrophil count (ANC) ≥ 1,500/mL; platelets ≥ 100,000/mL; hemoglobin ≥ 9 gm/dL; total bilirubin ≥ upper limit of normal; and creatinine ≥1. 
Treatment
Construction of the MV-NIS virus has been previously described (27) : a schematic representation of the MV-NIS genome is included in Supplementary Figure 1 . Clinical lots of the virus were produced by the Mayo Clinic Gene and Virus Therapy Shared Resource (GVTSR).
During the course of the study a new FDA approved vector production methodology was developed by GVTSR employing HeLa as the producer cell line, which allowed production of clinical grade vector in higher titers as compared to the original Vero cell based methodology (28) . All patients underwent laparotomy or laparoscopy, for placement of the intraperitoneal catheter (Bard Access Systems). Peritoneal adhesions were lysed if technically possible. If ascites was present, it was drained through the peritoneal catheter before the viral administration. Patients received infusion of the MV-NIS diluted in 500 mL of normal saline over 30 minutes. Treatment was repeated monthly for up to 6 cycles, provided that toxicity was acceptable and there was no evidence of disease progression.
Experimental Design and Statistical Analysis
The standard cohorts-of-three design (29) was applied. There were two dose levels (10 
Assessment of antitumor response
Response Evaluation Criteria in Solid Tumors criteria (30) were applied for response assessment.
Computed tomography or magnetic resonance imaging and CA-125 measurements were done at baseline and before retreatment on cycles 2-6.
Detection and quantitation of Measles Virus N-gene RNA by QRT-PCR in peripheral blood mononuclear cells, mouth gargle and urine specimens
Total RNA was extracted using either Trizol MV-N gene copies/ml is used in the assay. Calculation of copy number was determined using the standard curve and the Roche480 machine Absolute quantification software.
Assessment of CD46 and Nectin-4 expression in ovarian tumors
Immunohistochemistry for CD46: The primary antibody CD46 (EPR4014) (AbCam Cat# ab108307) was diluted 1:500, and slides were incubated overnight, at 4°C in a humidified chamber, then incubated with a Donkey Anti rabbit IgG-B biotinylated secondary antibody (Santa Cruz Biotech. Inc., Cat # sc-2040) for 60 minutes at room temperature, followed by a detection step with Vectastain ABC and Peroxidase substrate DAB kits (Vector Labs. Inc., PK-6100 and Cat # SK-4100), counterstained using Accustain solution (Sigma, Cat # GSH-116), then dehydrated and mounted using VectaMount H-5000 permanent mounting solution (Vector labs Cat# H-5000).
Immunochemistry for Nectin 4:
The primary antibody Nectin4 MAB2659 (R&D Systems Cat# AF2659) was diluted 1:500 and the slides were incubated overnight, at 4°C in a humidified chamber. For the next step, a secondary antibody reagent part of a Tissue staining Goat HRP-DAB system kit was used (Abcam Cat# CTS008) according to the manufacturer's instructions.
After the detection step the slides were counterstained using Accustain solution, dehydrated and mounted using VectaMount H-5000 solution.
Assessment of humoral immune response against MV
This was tested using the Diamedix Immunoassay, as per the manufacturer's instructions.
Assessment of cellular immune response against OvCa antigens
IFN-gamma and IL-4 ELIspots were performed as previously described except that a 48 hour rather 10-day format was used (31) . To detect anti-specific T cell immunity a degenerate panel of peptides derived from either the folate receptor alpha (FRα) (FR30, FR56, FR113, and FR238 ) or insulin like growth factor binding protein 2 (IGFBP2) (IGFBP2.17, IGFBP2.22, IGFBP2.249, and IGFBP2.293) previously described were used (32, 33) . The plates were read on an AID ELISpot reader (Cell Technology, Inc., Columbia MD, reader software v.3.1.1.). A positive response was defined as a frequency that was both detectable (i.e., > 1:100,000) and significantly (p < 0.05, two-tailed t test) greater than the mean of control no-antigen wells. Results are presented as the sum of the antigen-specific effector T cells for each peptide and each antigen.
Results
Patient Characteristics
Sixteen patients with recurrent ovarian cancer were treated in this phase I trial. Table 1 summarizes the patients' characteristics. All participating patients had platinum resistant disease and had been heavily pretreated having received a median of 4 chemotherapy regimens for recurrent disease. 
Expression of the MV-NIS receptor CD46 and nectin-4 in tumor specimens
Immunohistochemical analysis of baseline tumor samples from study patients showed moderate or high expression of CD46 and nectin-4 MV receptors in all patients ( Figures 2C and 2D respectively). Specifically 3/14 (21%) patients had moderate CD46 expression and 10/14 (71%) patients had high CD46 expression, while 1/14 patients (7%) had moderate nectin-4 expression and 13/14 (93%) had high nectin-4 expression. Of note, the one patient who was negative for CD46 had high nectin-4 expression. 
Assessment of Viral Biodistribution and Shedding
There was no evidence of shedding as tested by quantitative RT-PCR in mouth gargle and urine specimens for any of the study patients at the prespecified time points, and no detection of viral genomes in peripheral blood. Figure 3 depicts mean serum antimeasles antibody levels in the serum at baseline and on study completion according to dose levels. As per study eligibility, all patients were measles immune at baseline. There was no significant change in the measles antibody titers in blood and peritoneal fluid (data not shown) during the course of the trial, as compared to baseline. 
Assessment of immune response to measles virus
Detection of the NIS transgene
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Treatment with MV-NIS augments endogenous immunity against tumor antigens.
Although our initial phase I studies were not designed to collect and preserve T cells for functional analysis, the observed clinical benefit in some of the study patients in the context of minimal residual disease raised the possibility that in addition to oncolysis, other mechanisms such as the development of an antitumor immune response might be contributing to the favorable clinical outcomes. We therefore collected pre-and post-treatment specimens in a subgroup of study patients to investigate the possible immunotherapeutic potential of this approach and address the vaccine effects of MV and the role of antitumor immunity in the clinical efficacy of MV treatment. Figure 5 shows the results of an IFN-γ ELIspot analysis of the specimens obtained from 4 MV-NIS treated patients, demonstrating that MV treatment activates tumor antigen-specific T cells. In that experiment, peripheral blood T cells were stimulated with a pool of HLA-DR epitopes derived from the folate receptor alpha (FRα) or insulin like growth factor binding protein 2 (IGFBP2). Both of these antigens are highly expressed in a high percentage of ovarian cancer patients and some patients with ovarian cancer demonstrate natural immunity to these antigens (32, 36) . As shown, patients treated with MV-NIS augmented immune responses to both antigens but not to tetanus (TT) which was added as a control for specificity of the immune response. Similar results were obtained when an IL-4 ELISPOT analysis for the same antigens was performed. In addition, pre-and post-treatment sera samples, available from 31 patients that received either MV-CEA or MV-NIS, were tested to detect antibodies targeting FRα, HER-2, CEA, and IGFBP2; no responses to any of the antigens were generated. It is also interesting that the long median overall survival in study patients was associated with a relatively short median time to progression. Although the latter could reflect the very aggressive imaging schedule followed in this trial with CTs obtained every month, the survival benefit could also be indicative of a different mechanism of action, beyond oncolysis, contributing to the antitumor effect, such as an immune-based mechanism. Although the correlative analysis in this trial was designed to examine the oncolytic mechanism of action, several findings suggest studying means to avoid immune capture of the virus and thus facilitate its delivery to the tumor, such as using mesenchymal stem cells for viral delivery (45) .
Based on the results of the phase I/II study of MV-NIS reported here, we have designed a randomized phase II trial comparing intraperitoneal administration of MV-NIS with the treating physician's chemotherapy of choice for patients with recurrent ovarian cancer and low disease burden, where the virus has a higher likelihood of also working as effective immunotherapy.
Given the favorable toxicity profile of the virus as compared to all standard chemotherapy approaches, outcomes to be evaluated in the study include patient reported outcomes such as quality of life in addition to efficacy and toxicity assessment. This trial will also include a prospective immunologic analysis, and thus is expected to provide additional information on a possible immune-mediated mechanism of action of MV-NIS and guide future steps including combinatorial strategies with other immunomodulatory approaches such as immune checkpoint blockade (46, 47).
In summary, intraperitoneal administration of MV-NIS in patients with recurrent ovarian cancer, was associated with compelling survival outcomes and merits further prospective testing.
Moreover, this study has generated mechanistic hypotheses regarding a novel immune based mechanism of MV action that we are planning to explore in additional trials. 
